Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. Ng ZY, et al. Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24. Hematol Oncol. 2019. PMID: 30983008
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP. Bishton MJ, et al. Br J Haematol. 2016 Jan;172(2):246-54. doi: 10.1111/bjh.13831. Epub 2015 Nov 18. Br J Haematol. 2016. PMID: 26577576
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS. Reyal Y, et al. Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14. Biol Blood Marrow Transplant. 2016. PMID: 27095691 Free article.
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY. Barraclough A, et al. Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251. Blood Adv. 2019. PMID: 31285189 Free PMC article.
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, Creasey T, Goradia H, McMillan A, Dawi S, Harrison S, Miles O, Robinson A, Dutton D, Wilson MR, McKay P, Follows G, Phillips N, Patmore R, Lambert J, Bishton M, Osborne W, Johnston R, Kirkwood AA, Rule S. McCulloch R, et al. Br J Haematol. 2021 Apr;193(2):290-298. doi: 10.1111/bjh.17363. Epub 2021 Feb 23. Br J Haematol. 2021. PMID: 33620106 Free article.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, McKay P, Ebsworth T, Miller J, Shah N, Martinez-Calle N, Bishton M, Everden A, Tucker D, El-Hassad E, Hennessy B, Doherty D, Prideaux S, Faryal R, Hayat A, Keohane C, Marr H, Gibb A, Pocock R, Lambert J, Lacey R, Elmusharaf N, Clifford R, Eyre TA. Rampotas A, et al. Br J Haematol. 2021 Jul;194(2):365-377. doi: 10.1111/bjh.17513. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33959947
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP. Martinez-Calle N, et al. Adv Ther. 2021 Jul;38(7):3789-3802. doi: 10.1007/s12325-021-01764-0. Epub 2021 May 26. Adv Ther. 2021. PMID: 34037958 Free PMC article.
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Kaji FA, Martinez-Calle N, Bishton MJ, Figueroa R, Adlington J, O'Donoghue M, Smith S, Byrne P, Paine S, Sovani V, Auer D, James E, Bessell EM, Grainge MJ, Fox CP. Kaji FA, et al. Br J Haematol. 2021 Nov;195(4):561-570. doi: 10.1111/bjh.17747. Epub 2021 Aug 8. Br J Haematol. 2021. PMID: 34368948
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, Doo NW, Li EW, Gilbertson M, Shaw B, Bishton MJ, Saeed M, Ratnasingam S, Abeyakoon C, Chong G, Wai SH, Ku M, Lee HP, Fleming K, Tam C, Douglas G, Cheah CY, Ng ZY, Rolfe T, Mills AK, Hamad N, Cashman H, Gleeson M, Narayana M, Hawkes EA. Barraclough A, et al. Haematologica. 2023 Sep 1;108(9):2444-2453. doi: 10.3324/haematol.2022.281375. Haematologica. 2023. PMID: 36815381 Free PMC article.
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. Lewis KL, et al. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5. J Clin Oncol. 2023. PMID: 37797284
Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
Minson A, Hamad N, Di Ciaccio P, Talaulikar D, Ku M, Ratnasingam S, Cheah C, Yannakou CK, Bishton M, Ng ZY, Agrawal S, McQuillan A, Johnston A, Choong E, Wong K, McQuillan J, Beekman A, Hawkes E, Dickinson M. Minson A, et al. Br J Haematol. 2024 Feb;204(2):548-554. doi: 10.1111/bjh.19179. Epub 2023 Oct 30. Br J Haematol. 2024. PMID: 37904342
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
Wilson MR, Lewis KL, Kirkwood AA, Cwynarski K, Cheah CY, El-Galaly TC, Villa D, Savage KJ, Ghione P, Bobillo S, Smedby KE, Harrysson S, Trneny M, Klanova M, Puckrin R, Fox CP, Bishton M, Thanarajasingam G, Wong Doo N, Hapgood G, Soussain C, Choquet S, Dickinson M, Talaulikar D, de Mel S, Preston G, Ahearne M, Hawkes EA, Schorb E, Clavert A, Ku M, Guidetti A, Narkhede M, Calimeri T, Durot E, Smith J, Renaud L, McKay P, Eyre TA. Wilson MR, et al. Among authors: bishton m. J Clin Oncol. 2026 Jun 11:JCO2600947. doi: 10.1200/JCO-26-00947. Online ahead of print. J Clin Oncol. 2026. PMID: 42274647
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR. Eyre TA, et al. J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11. J Intern Med. 2019. PMID: 30811713 Free article.
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. Br J Haematol. 2019. PMID: 31020646 No abstract available.
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. Eyre TA, et al. Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31222719
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
González-Barca E, Boumendil A, Blaise D, Trněný M, Masszi T, Finel H, Michieli MG, Bittenbring JT, Gritti G, Snowden JA, Bishton M, Bruno B, de Villambrosia SG, Janikova A, Leleu X, Anagnostopoulos A, Poiré X, Crysandt M, Özkurt ZN, Vandenberghe E, Itälä-Remes M, Cahn JY, Jantunen E, Schroyens W, Maertens J, Esquirol A, Dreger P, Montoto S, Sureda A. González-Barca E, et al. Bone Marrow Transplant. 2020 Feb;55(2):393-399. doi: 10.1038/s41409-019-0650-x. Epub 2019 Sep 20. Bone Marrow Transplant. 2020. PMID: 31541205 Free article.
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Bishton MJ, Rule S, Wilson W, Turner D, Patmore R, Clifton-Hadley L, McMillan A, Lush R, Haynes A. Bishton MJ, et al. Br J Haematol. 2020 Aug;190(4):545-554. doi: 10.1111/bjh.16555. Epub 2020 Mar 9. Br J Haematol. 2020. PMID: 32150649 Clinical Trial.
The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M, Marshall S, Harchowal J, Salles G, Golfier C, Tucci A, Fernández AR, Sanchez Blanco JJ, Bocchia M, Kim S, Lee YN, Zinzani PL. Bishton M, et al. Hematol Oncol. 2022 Aug;40(3):370-380. doi: 10.1002/hon.2978. Epub 2022 Mar 17. Hematol Oncol. 2022. PMID: 35168291 Free PMC article.
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Arulogun SO, Brian D, Goradia H, Cooney A, Menne T, Koo R, O'Neill AT, Vos JMI, Pratt G, Turner D, Marshall K, Manos K, Anderson C, Gavriatopoulou M, Kyriakou C, Kersten MJ, Minnema MC, Koutoumanou E, El-Sharkawi D, Linton K, Talaulikar D, McCarthy H, Bishton M, Follows G, Wechalekar A, D'Sa SP. Arulogun SO, et al. Am J Hematol. 2023 May;98(5):750-759. doi: 10.1002/ajh.26895. Epub 2023 Mar 20. Am J Hematol. 2023. PMID: 36866925 Free article.
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Shpilberg O, da Silva MG, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Heß G, Meerten TV, Wirths S, Herhaus P, Novak U, Dierlamm J, Hänel M, Hanoun C, Sonnevi K, Visco C, Donnarumma D, Ferreri AJM, Patti C, Stefani PM, Pott C, Klapper W, Schmidt C, Unterhalt M, Tix T, Ladetto M, Hoster E; European Mantle Cell Lymphoma Network. Dreyling M, et al. Lancet. 2026 May 16;407(10542):1953-1967. doi: 10.1016/S0140-6736(26)00362-4. Lancet. 2026. PMID: 42134356 Free article. Clinical Trial.
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S; ENRICH investigators. Lewis DJ, et al. Among authors: bishton mj. Lancet. 2025 Oct 25;406(10514):1953-1968. doi: 10.1016/S0140-6736(25)01432-1. Epub 2025 Oct 3. Lancet. 2025. PMID: 41052510 Free PMC article. Clinical Trial.
Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP. Martínez-Calle N, et al. Br J Haematol. 2019 Mar;184(6):957-968. doi: 10.1111/bjh.15722. Epub 2018 Dec 13. Br J Haematol. 2019. PMID: 30548597
Spinal epidural lipomatosis in myeloma.
Liew MS, Bishton MJ, Januszewicz H, Alatakis S, Prince HM. Liew MS, et al. Leuk Lymphoma. 2007 Oct;48(10):2068-70. doi: 10.1080/10428190701593651. Leuk Lymphoma. 2007. PMID: 17852706 No abstract available.
Clinical studies of histone deacetylase inhibitors.
Prince HM, Bishton MJ, Harrison SJ. Prince HM, et al. Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509172 Review.
The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.
Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y. Mansour M, et al. Cancer Res. 2016 Jul 15;76(14):4236-48. doi: 10.1158/0008-5472.CAN-15-1553. Epub 2016 May 26. Cancer Res. 2016. Retraction in: Cancer Res. 2019 Jun 1;79(11):3008. doi: 10.1158/0008-5472.CAN-19-1133. PMID: 27231202 Retracted.
Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
Wilson MR, Lewis KL, Kirkwood AA, Cwynarski K, Cheah CY, El-Galaly TC, Villa D, Savage KJ, Ghione P, Bobillo S, Smedby KE, Harrysson S, Trneny M, Klanova M, Puckrin R, Fox CP, Bishton M, Thanarajasingam G, Doo NW, Hapgood G, Soussain C, Choquet S, Dickinson M, Talaulikar D, de Mel S, Preston G, Ahearne M, Hawkes EA, Schorb E, Clavert A, Ku M, Guidetti A, Narkhede M, Calimeri T, Durot E, Smith J, Renaud L, McKay P, Eyre TA. Wilson MR, et al. Among authors: bishton m. J Clin Oncol. 2026 Jul 27:JCO2601800. doi: 10.1200/JCO-26-01800. Online ahead of print. J Clin Oncol. 2026. PMID: 42507971 No abstract available.
Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial.
Williams S, Lim YJ, Cooper R, Gamble C, Short H, Arumainathan A, Eyre TA, McKay P, Young M, Bishton M, Gatto S, Macheta M, Zhelyazkova A, Heartin E, Miall F, Warbey V, Opat S, Johnston A, Trotman J, Linton K, Pettitt A. Williams S, et al. Among authors: bishton m. Br J Haematol. 2026 Jul 16. doi: 10.1111/bjh.70656. Online ahead of print. Br J Haematol. 2026. PMID: 42463998 No abstract available.
Trends in mortality due to haemophagocytic lymphohistiocytosis across 29 European countries from 2011 to 2021: a retrospective, international, population-based study.
Gumber L, Omidvar R, Gonnelli F, Taylor A, Trimble T, Bishton M, Collin M, Hubbard R, Lanyon PC, Tattersall RS, Manson JJ, Pearce FA. Gumber L, et al. Among authors: bishton m. Lancet Rheumatol. 2026 Feb;8(2):e108-e115. doi: 10.1016/S2665-9913(25)00292-9. Epub 2025 Nov 29. Lancet Rheumatol. 2026. PMID: 41325766 Free article.
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.
Zelenetz AD, Jurczak W, Ribrag V, Linton K, Collins GP, Jiménez JL, Bishton M, Dholaria B, Mengarelli A, Phillips TJ, Sungala N, Musuraca G, Sheehy O, Van Den Neste E, Odera M, Miao L, Gold DP, Ghalie RG, Zinzani PL. Zelenetz AD, et al. Hemasphere. 2024 Aug 6;8(8):e138. doi: 10.1002/hem3.138. eCollection 2024 Aug. Hemasphere. 2024. PMID: 39108321 Free PMC article.
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
McIlroy G, Lax S, Gaskell C, Jackson A, Rhodes M, Seale T, Fox S, Hopkins L, Okosun J, Barrington SF, Ringshausen I, Ramsay AG, Calaminici M, Linton K, Bishton M. McIlroy G, et al. BMC Cancer. 2024 Mar 25;24(1):370. doi: 10.1186/s12885-024-12112-0. BMC Cancer. 2024. PMID: 38528445 Free PMC article.
Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.
Cox MF, Mackenzie S, Low R, Brown M, Sanchez E, Carr A, Carpenter B, Bishton M, Duncombe A, Akpabio A, Kulasekararaj A, Sin FE, Jones A, Kavirayani A, Sen ES, Quick V, Dulay GS, Clark S, Bauchmuller K, Tattersall RS, Manson JJ; HiHASC group. Cox MF, et al. Lancet Rheumatol. 2024 Jan;6(1):e51-e62. doi: 10.1016/S2665-9913(23)00273-4. Epub 2023 Nov 29. Lancet Rheumatol. 2024. PMID: 38258680 Review.
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Tivey A, Shotton R, Eyre TA, Lewis D, Stanton L, Allchin R, Walter H, Miall F, Zhao R, Santarsieri A, McCulloch R, Bishton M, Beech A, Willimott V, Fowler N, Bedford C, Goddard J, Protheroe S, Everden A, Tucker D, Wright J, Dukka V, Reeve M, Paneesha S, Prahladan M, Hodson A, Qureshi I, Koppana M, Owen M, Ediriwickrema K, Marr H, Wilson J, Lambert J, Wrench D, Burney C, Knott C, Talbot G, Gibb A, Lord A, Jackson B, Stern S, Sutton T, Webb A, Wilson M, Thomas N, Norman J, Davies E, Lowry L, Maddox J, Phillips N, Crosbie N, Flont M, Nga E, Virchis A, Camacho RG, Swe W, Pillai A, Rees C, Bailey J, Jones S, Smith S, Sharpley F, Hildyard C, Mohamedbhai S, Nicholson T, Moule S, Chaturvedi A, Linton K. Tivey A, et al. Blood Adv. 2024 Mar 12;8(5):1209-1219. doi: 10.1182/bloodadvances.2023011152. Blood Adv. 2024. PMID: 38127279 Free PMC article.
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Shotton R, Broadbent R, Alchawaf A, Mohamed MB, Gibb A, Martinez-Calle N, Fox CP, Bishton M, Pender A, Gleeson M, Cunningham D, Davies A, Yadollahi S, Eyre TA, Collins G, Djebbari F, Kassam S, Garland P, Watts E, Osborne W, Townsend W, Pocock R, Ahearne MJ, Miall F, Wang X, Linton KM. Shotton R, et al. Blood Adv. 2024 Feb 27;8(4):878-888. doi: 10.1182/bloodadvances.2023011305. Blood Adv. 2024. PMID: 37967358 Free PMC article.